Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Inovio Pharmaceuticals said the FDA completed a standard mid-cycle review of its BLA for INO-3107 for recurrent respiratory papillomatosis, with “no new significant issues,” and scheduled the late-cycle review for Q3. The company expects an informal meeting on an Accelerated Approval eligibility question. Inovio reported $37.7M cash at Q1 2026, reduced 2025 operating spend 23%, and expects runway into Q1 2027.
How this was made
The 30-second read
Why it matters
The FDA’s “no new significant issues” mid-cycle result and scheduled late-cycle review for Q3 reduce near-term regulatory uncertainty, while an upcoming informal meeting on a potential eligibility issue keeps a tail risk.
Market read
Regulatory milestone timing (Q3 late-cycle review) is the core catalyst, with additional support from cost discipline and cash runway into early 2027.
What to watch
The article doesn’t quantify probability of approval or address potential manufacturing/CMC or confirmatory-trial requirements that can still affect outcome despite a clean mid-cycle review.
Background
Inovio is advancing INO-3107 for RRP (rare HPV-related disease) and is seeking Accelerated Approval based on efficacy/tolerability data aimed at reducing surgeries.
Ticker impact
Inovio said the FDA completed the mid-cycle BLA review for INO-3107 with no new significant issues and set late-cycle review for Q3.
Near-term upside bias into Q3 as investors price in a smoother late-cycle review; volatility likely around any eligibility discussion tied to Accelerated Approval.
The article cites specific FDA review milestones (mid-cycle completion, no new issues, late-cycle timing) and frames INO-3107 as meeting Accelerated Approval eligibility, which directly affects approval odds and timing.
Market effects
Supports risk-on sentiment for DNA-based immunotherapy platforms and HPV/RRP immunotherapy development narratives.
Primarily US biotech/biopharma sentiment; no direct regional macro catalyst described.
Limited direct global impact beyond FDA review timing; partnerships and platform claims may attract international biotech attention.
Counterpoint
The FDA may still raise an eligibility-related issue from the acceptance letter during the informal meeting, which could delay or complicate the Accelerated Approval path.
Key entities
- drug_candidateINO-3107
Inovio’s therapy under FDA BLA review for RRP, with mid-cycle review completed and late-cycle review scheduled for Q3.
- partnerAkeso
Partnered with Inovio to evaluate INO-5401 with Akeso’s dual checkpoint inhibitor in a Phase 2 adaptive platform trial for glioblastoma.
- research_partnerThe Wistar Institute
Collaborates with Inovio on DNA-encoded monoclonal antibody technology and related proof-of-concept work.
- partnerAstraZeneca
Named as a collaborator with Inovio on DNA-encoded protein/monoclonal antibody technology development.
